Europe Biosimilars Market to 2030 - By Size, Share, Growth by End User and Forecast

1. Introduction

1.1 Business Market Insights Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:

4. Europe Biosimilars Market Landscape

4.1 Market Overview

4.2 Porter's Five Forces Analysis

4.2.1 Bargaining Power of Suppliers
4.2.2 Bargaining Power of Buyers
4.2.3 Threat of New Entrants
4.2.4 Competitive Rivalry
4.2.5 Threat of Substitutes

4.3 Ecosystem Analysis

4.3.1 Raw Material Suppliers
4.3.2 Manufacturers
4.3.3 Distributors/Suppliers
4.3.4 End Users

5. Europe Biosimilars Market – Key Market Dynamics

5.1 Growth Drivers

5.1.1 Rising demand for biosimilars due to cost-effectiveness
5.1.2 Expanding use of biosimilars in oncology and immunology

5.2 Market Opportunities

5.2.1 Adoption of biosimilars to lower healthcare costs
5.2.2 Expansion into emerging markets with biosimilar drugs

5.3 Future Trends

5.3.1 Growing adoption of biosimilars
5.3.2 Support for biosimilar approvals

5.4 Impact of Drivers and Restraints

6. Europe Biosimilars Market Regional Analysis

6.1 Europe Biosimilars Market Overview

6.2 Europe Biosimilars Market Revenue 2020-2030 (US$ Million)

6.3 Europe Biosimilars Market Forecast Analysis

7. Europe Biosimilars Market Analysis – by Disease Indication

7.1 Cancer

7.1.1 Overview
7.1.2 Cancer: Europe Biosimilars Market – Revenue and Forecast to 2031 (US$ Million)

7.2 Diabetes

7.2.1 Overview
7.2.2 Diabetes: Europe Biosimilars Market – Revenue and Forecast to 2031 (US$ Million)

7.3 Autoimmune Disease

7.3.1 Overview
7.3.2 Autoimmune Disease: Europe Biosimilars Market – Revenue and Forecast to 2031 (US$ Million)

7.4 Other Disease Indication

7.4.1 Overview
7.4.2 Other Disease Indication: Europe Biosimilars Market – Revenue and Forecast to 2031 (US$ Million)

8. Europe Biosimilars Market Analysis – by Route of Administration

8.1 Intravenous

8.1.1 Overview
8.1.2 Intravenous: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

8.2 Subcutaneous

8.2.1 Overview
8.2.2 Subcutaneous: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

9. Europe Biosimilars Market Analysis – by Drug Class

9.1 Granulocyte Colony-Stimulating Factor

9.1.1 Overview
9.1.2 Subcutaneous: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

9.2 Insulin

9.2.1 Overview
9.2.2 Subcutaneous: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

9.3 TNF Blockers and Monoclonal Antibodies

9.3.1 Overview
9.3.2 Subcutaneous: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

10. Europe Biosimilars Market – Europe Analysis

10.1 Europe

10.1.1 Europe Biosimilars Market Breakdown, by Key Country, 2023 and 2030 (%)
10.1.1.1 Europe Biosimilars Market – Revenue and Forecast Analysis – by Country
10.1.1.1 UK: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

10.1.1.1.1 UK: Europe Biosimilars Market Breakdown, by Disease Indication
10.1.1.1.2 UK: Europe Biosimilars Market Breakdown, by Route of Administration
10.1.1.1.3 UK: Europe Biosimilars Market Breakdown, by Drug Class

10.1.1.2 Germany: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

10.1.1.2.1 Germany: Europe Biosimilars Market Breakdown, by Disease Indication
10.1.1.2.2 Germany: Europe Biosimilars Market Breakdown, by Route of Administration
10.1.1.2.3 Germany: Europe Biosimilars Market Breakdown, by Drug Class

10.1.1.3 France: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

10.1.1.3.1 France: Europe Biosimilars Market Breakdown, by Disease Indication
10.1.1.3.2 France: Europe Biosimilars Market Breakdown, by Route of Administration
10.1.1.3.3 France: Europe Biosimilars Market Breakdown, by Drug Class

10.1.1.4 Russia: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

10.1.1.4.1 Russia: Europe Biosimilars Market Breakdown, by Disease Indication
10.1.1.4.2 Russia: Europe Biosimilars Market Breakdown, by Route of Administration
10.1.1.4.3 Russia: Europe Biosimilars Market Breakdown, by Drug Class

10.1.1.5 Italy: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

10.1.1.5.1 Italy: Europe Biosimilars Market Breakdown, by Disease Indication
10.1.1.5.2 Italy: Europe Biosimilars Market Breakdown, by Route of Administration
10.1.1.5.3 Italy: Europe Biosimilars Market Breakdown, by Drug Class

10.1.1.6 Rest of Europe: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

10.1.1.6.1 Rest of Europe: Europe Biosimilars Market Breakdown, by Disease Indication
10.1.1.6.2 Rest of Europe: Europe Biosimilars Market Breakdown, by Route of Administration
10.1.1.6.3 Rest of Europe: Europe Biosimilars Market Breakdown, by Drug Class

11. Competitive Landscape

11.1 Heat Map Analysis

11.2 Company Positioning and Concentration

12. Europe Biosimilars Market Industry Landscape

12.1 Overview

12.2 Mergers and Acquisitions

12.3 Agreements, Collaborations, and Joint Ventures

12.4 New Product Launches

12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 Amgen Inc

13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments

13.2 Celltrion Inc

13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments

13.3 Sanofi SA

13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments

13.4 Biocon Ltd,

13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments

13.5 Samsung Bioepis Co Ltd

13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments

13.6 Elli Lilly and Co

13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments

13.7 Sandoz AG

13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments

13.8 Teva Pharmaceitical Industries Ltd

13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments

13.9 Pfizer Inc

13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments

13.10 Dr. Reddy's Laboratories Ltd

13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments

14. Appendix

14.1 About Business Market Insights

The List of Companies - E Market

Amgen Inc
Celltrion Inc
Sanofi SA
Biocon Ltd,
Samsung Bioepis Co Ltd
Elli Lilly and Co
Sandoz AG
Teva Pharmaceitical Industries Ltd
Pfizer Inc
Dr. Reddy's Laboratories Ltd